Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of BMS-986231 in hospitalized heart failure with reduced systolic function
2016-001685-29Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) and heart failure with reduced ejection fraction (HFrEF) comparing BMS-986231 dose-ranging IV infusion with Placebo IV infusion (2 arms). Primary endpoint: Clinically relevant hypotension incidence. Started Dec 2016; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2016-001685-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001685-29.